WHAT IS CLAIMED IS:

1. A storage stable, aqueous immunoglobulin composition comprising:
(a) an immunoglobulin
(b) from 50 mM to 500 mM histidine;
(c) from 0 mM to 10 mM of an alkali metal cation; and
(d) a pH from 5.5 to 7.0.

2. The composition according to claim 1, containing from 150 mM to 350 mM histidine.

3. The composition of claim 2, containing from 225 mM to 275 mM histidine.

4. The composition according to any one of claims 1 to 3, containing from 0 mM to 1 mM of an alkali metal cation.

5. The composition according to any one of claims 1 to 4, wherein the composition contains from 10 mM to 400 mM chloride ions.

6. The composition of claim 5, containing from 100 mM to 200 mM chloride ions.

7. The composition according to any one of claims 1 to 6, wherein the pH of the composition is from 5.5 to 6.5.

8. The composition of claim 7, wherein the pH of the composition is 6.1±0.2.

9. The composition according to any one of claims 1 to 8, wherein the composition further comprises an antioxidant.

10. The composition according to any one of claims 1 to 9, wherein the composition does not contain a surfactant or sugar.

11. The composition according to any one of claims 1 to 10, wherein the composition is stored under an inert gas.

12. The composition of claim 11, wherein the inert gas is selected from the group consisting of nitrogen, argon, carbon dioxide, helium, krypton, and xenon.

13. The composition of claim 11, wherein the inert gas is nitrogen.

14. The composition of claim 11, wherein the inert gas is argon.

15. The composition according to any one of claims 1 to 14, wherein the immunoglobulin is a polyclonal immunoglobulin.

16. The composition according to any one of claims 1 to 14, wherein the immunoglobulin is a monoclonal immunoglobulin.

17. The composition according to any one of claims 1 to 16, wherein the immunoglobulin is an IgG immunoglobulin.

18. The composition according to any one of claims 1 to 17, wherein the immunoglobulin is enriched from pooled human plasma.

19. The composition according to any one of claims 1 to 17, wherein the immunoglobulin is a recombinant immunoglobulin.

20. The composition according to any one of claims 1 to 19, wherein the concentration of the immunoglobulin is 50±5 g/L.

21. The composition according to any one of claims 1 to 19, wherein the concentration of the immunoglobulin is less than 50 g/L.

22. The composition according to any one of claims 1 to 19, wherein the concentration of the immunoglobulin is at least 50 g/L.

23. The composition of claim 22, wherein the concentration of the immunoglobulin is from 50 g/L to 150 g/L.

24. The composition of claim 23, wherein the concentration of the immunoglobulin is 100±10 g/L.

25. The composition of claim 22, wherein the concentration of the immunoglobulin is at least 100 g/L.

26. The composition of claim 25, wherein the concentration of the immunoglobulin is 150±15 g/L.

27. The composition of claim 25, wherein the concentration of the immunoglobulin is from 150 g/L to 250 g/L.

28. The composition of claim 27, wherein the concentration of the immunoglobulin is 200±20 g/L.

29. The composition of claim 22, wherein the concentration of the immunoglobulin is at least 200 g/L.

30. The composition according to any one of claims 1 to 29, wherein the composition is stable for at least 1 month when stored at from 38°C to 42°C.

31. The composition of claim 30, wherein the composition is stable for at least 3 months when stored at from 38°C to 42°C.

32. The composition of claim 31, wherein the composition is stable for at least 6 months when stored at from 38°C to 42°C.

33. The composition according to any one of claims 1 to 32, wherein the composition is stable for at least 6 months when stored at from 28°C to 32°C.

34. The composition of claim 33, wherein the composition is stable for at least 1 year when stored at from 28°C to 32°C.

35. The composition of claim 34, wherein the composition is stable for at least 2 years when stored at from 28°C to 32°C.

36. The composition according to any one of claims 1 to 35, wherein the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state remains below 2%.

37. The composition according to any one of claims 1 to 35, wherein the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state is from 0% to 2% and the percentage of immunoglobulin in the monomeric state is from 85% to 100%.

38. The composition according to any one of claims 1 to 37, wherein a composition having the same components, but formulated at pH 4.8, is stable for less than 1 month when stored at from 38°C to 42°C.

39. The composition according to any one of claims 1 to 38, wherein a composition having the same components, but formulated at pH 4.8, is stable for less than 6 months when stored at from 28°C to 32°C.

40. A method for stabilizing an immunoglobulin composition, the method comprising formulating the composition at a pH between 5.5 and 7.0,

wherein the formulated composition comprises:

(a) an immunoglobulin

(b) from 50 mM to 500 mM histidine; and

(c) from 0 mM to 10 mM of an alkali metal cation.

41. The method according to claim 40, wherein the formulated composition contains from 150 mM to 350 mM histidine.

42. The method according to claim 41, wherein the formulated composition contains from 225 mM to 275 mM histidine.

43. The method according to any one of claims 40 to 42, wherein the formulated composition contains from 0 mM to 1 mM of an alkali metal cation.

44. The method according to any one of claims 40 to 43, wherein the formulated composition contains from 10 mM to 400 mM chloride ions.

45. The method according to claim 44, wherein the formulated composition contains from 100 mM to 200 mM chloride ions.

46. The method according to any one of claims 40 to 45, wherein the pH of the formulated composition is from 5.5 to 6.5.

47. The method according to claim 46, wherein the pH of the formulated composition is 6.1±0.2.

48. The method according to any one of claims 40 to 47, wherein the formulated composition further comprises an antioxidant.

49. The method according to any one of claims 40 to 48, wherein the formulated composition does not contain a surfactant or sugar.

50. The method according to any one of claims 40 to 49, wherein the formulated composition is stored under an inert gas.

51. The method according to claim 50, wherein the inert gas is selected from the group consisting of nitrogen, argon, carbon dioxide, helium, krypton, and xenon.

52. The method according to claim 50, wherein the inert gas is nitrogen.

53. The method according to claim 50, wherein the inert gas is argon.

54. The method according to any one of claims 40 to 53, wherein the immunoglobulin is a polyclonal immunoglobulin.

55. The method according to any one of claims 40 to 53, wherein the immunoglobulin is a monoclonal immunoglobulin.

56. The method according to any one of claims 40 to 55, wherein the immunoglobulin is an IgG immunoglobulin.

57. The method according to any one of claims 40 to 56, wherein the immunoglobulin is enriched from pooled human plasma.

58. The method according to any one of claims 40 to 56, wherein the immunoglobulin is a recombinant immunoglobulin.

59. The method according to any one of claims 40 to 58, wherein the concentration of the immunoglobulin in the formulated composition is 50±5 g/L.

60. The method according to any one of claims 40 to 58, wherein the concentration of the immunoglobulin in the formulated composition is less than 50 g/L.

61. The method according to any one of claims 40 to 58, wherein the concentration of the immunoglobulin in the formulated composition is at least 50 g/L.

62. The method according to claim 61, wherein the concentration of the immunoglobulin in the formulated composition is from 50 g/L to 150 g/L.

63. The method according to claim 62, wherein the concentration of the immunoglobulin in the formulated composition is 100±10 g/L.

64. The method according to claim 61, wherein the concentration of the immunoglobulin in the formulated composition is at least 100 g/L.

65. The method according to claim 64, wherein the concentration of the immunoglobulin in the formulated composition is 150±15 g/L.

66. The method according to claim 64, wherein the concentration of the immunoglobulin in the formulated composition is from 150 g/L to 250 g/L.

67. The method according to claim 64, wherein the concentration of the immunoglobulin in the formulated composition is 200±20 g/L.

68. The method according to claim 64, wherein the concentration of the immunoglobulin in the formulated composition is at least 200 g/L.

69. The method according to any one of claims 40 to 68, wherein the formulated composition is stable for at least 1 month when stored at from 38°C to 42°C.

70. The method according to claim 69, wherein the formulated composition is stable for at least 3 months when stored at from 38°C to 42°C.

71. The method according to claim 69, wherein the formulated composition is stable for at least 6 months when stored at from 38°C to 42°C.

72. The method according to any one of claims 40 to 71, wherein the formulated composition is stable for at least 6 months when stored at from 28°C to 32°C.

73. The method according to claim 72, wherein the formulated composition is stable for at least 1 year when stored at from 28°C to 32°C.

74. The method according to claim 72, wherein the formulated composition is stable for at least 2 years when stored at from 28°C to 32°C.

75. The method according to any one of claims 40 to 74, wherein the formulated composition is considered stable as long as the percentage of immunoglobulin in the aggregated state remains below 2%.

76. The method according to any one of claims 40 to 74, wherein the formulated composition is considered stable as long as the percentage of immunoglobulin in the aggregated state is from 0% to 2% and the percentage of immunoglobulin in the monomeric state is from 85% to 100%.

77. The method according to any one of claims 40 to 76, wherein an immunoglobulin composition having the same components as the formulated composition, but formulated at pH 4.8, is stable for less than 1 month when stored at from 38°C to 42°C.

78. The method according to any one of claims 40 to 77, wherein an immunoglobulin composition having the same components as the formulated composition, but formulated at pH 4.8, is stable for less than 6 months when stored at from 28°C to 32°C.

WHAT IS CLAIMED IS:

1. A storage stable, aqueous immunoglobulin composition comprising:

(a) an immunoglobulin

(b) from 225mM to 275 mM histidine;

(c) from 0 mM to 10 mM of an alkali metal cation; and

(d) a pH from 5.5 to 7.0,

wherein the composition is stable for at least 6 months when stored at from 28°C to 32°C, and wherein the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state remains below 2%, and wherein the composition does not contain a surfactant or sugar.

2. The composition of claim 1, containing from 0 mM to 1 mM of an alkali metal cation.

3. The composition of claim 1, wherein the composition contains from 10 mM to 400 mM chloride ions.

4. The composition of claim 3, containing from 100 mM to 200 mM chloride ions.

5. The composition of claim 1, wherein the pH of the composition is from 5.5 to 6.5.

6. The composition of claim 5, wherein the pH of the composition is 6.1±0.2.

7. The composition of claim 1, wherein the composition further comprises an antioxidant.

8. The composition of claim 1, wherein the composition is stored under an inert gas.

9. The composition of claim 8, wherein the inert gas is selected from the group consisting of nitrogen, argon, carbon dioxide, helium, krypton, and xenon.

10. The composition of claim 8, wherein the inert gas is nitrogen.

11. The composition of claim 8, wherein the inert gas is argon.

12. The composition of claim 1, wherein the immunoglobulin is a polyclonal immunoglobulin.

13. The composition of claim 1, wherein the immunoglobulin is a monoclonal immunoglobulin.

14. The composition of claim 1, wherein the immunoglobulin is an IgG immunoglobulin.

15. The composition of claim 1, wherein the immunoglobulin is enriched from pooled human plasma.

16. The composition of claim 1, wherein the immunoglobulin is a recombinant immunoglobulin.

17. The composition of claim 1, wherein the concentration of the immunoglobulin is 50±5 g/L.

18. The composition of claim 1, wherein the concentration of the immunoglobulin is less than 50 g/L.

19. The composition of claim 1, wherein the concentration of the immunoglobulin is at least 50 g/L.

20. The composition of claim 19, wherein the concentration of the immunoglobulin is from 50 g/L to 150 g/L.

21. The composition of claim 20, wherein the concentration of the immunoglobulin is 100±10 g/L.

22. The composition of claim 19, wherein the concentration of the immunoglobulin is at least 100 g/L.

23. The composition of claim 22, wherein the concentration of the immunoglobulin is 150±15 g/L.

24. The composition of claim 22, wherein the concentration of the immunoglobulin is from 150 g/L to 250 g/L.

25. The composition of claim 24, wherein the concentration of the immunoglobulin is 200±20 g/L.

26. The composition of claim 19, wherein the concentration of the immunoglobulin is at least 200 g/L.

27. The composition of claim 1, wherein the composition is stable for at least 1 month when stored at from 38°C to 42°C.

28. The composition of claim 27, wherein the composition is stable for at least 3 months when stored at from 38°C to 42°C.

29. The composition of claim 28, wherein the composition is stable for at least 6 months when stored at from 38°C to 42°C.

30. The composition of claim 1, wherein the composition is stable for at least 1 year when stored at from 28°C to 32°C.

31. The composition of claim 30, wherein the composition is stable for at least 2 years when stored at from 28°C to 32°C.

32. The composition of claim 1, wherein the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state is from 0% to 2% and the percentage of immunoglobulin in the monomeric state is from 85% to 100%.

33. The composition of claim 1, wherein a composition having the same components, but formulated at pH 4.8, is stable for less than 1 month when stored at from 38°C to 42°C.

34. The composition of claim 1, wherein a composition having the same components, but formulated at pH 4.8, is stable for less than 6 months when stored at from 28°C to 32°C.